Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD
Phase 3positiveprifemilastapremilastPositive
AI Analysis
Summary
Prifemilast demonstrated superior efficacy compared to apremilast in a head-to-head Phase 3 trial for psoriasis, nearly doubling PASI 75 response rates and meeting both co-primary endpoints, supporting its potential as a best-in-class oral PDE4 inhibitor.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Prifemilast nearly doubled PASI 75 response rate compared to apremilast and achieved superiority on both co-primary endpoints
Importance:8/10
Sentiment:
0.85
Phase 3psoriasisPDE4 inhibitorhead-to-head comparisonefficacyIBD
Read the original article
Published by PR Newswire Biotech on October 9, 2026 8:00 AM